Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: A randomized, placebo-controlled, double-blind, crossover study

British Journal of Clinical Pharmacology

Volumn 73, Issue 3, 2012, Pages 411-421

  Boyce, Malcolm J ^a   Baisley, Kathy J ^a   Warrington, Steven J ^a  

^a Hammersmith Medicines Research Limited and Trio Medicines Limited   (United Kingdom)

Author keywords

Domperidone; Drug interaction; Ketoconazole; Thorough QT

Indexed keywords

DOMPERIDONE; KETOCONAZOLE; PLACEBO;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; BODY WEIGHT; BREAST DISCHARGE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART VENTRICLE TACHYCARDIA; HUMAN; MALE; MASTALGIA; NORMAL HUMAN; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; STEADY STATE; TREATMENT DURATION;

14-ALPHA DEMETHYLASE INHIBITORS; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; ARRHYTHMIAS, CARDIAC; CROSS-OVER STUDIES; DOMPERIDONE; DOPAMINE ANTAGONISTS; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; KETOCONAZOLE; LONG QT SYNDROME; MALE; SEX FACTORS; YOUNG ADULT;

EID: 84856995147     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.04093.x     Document Type: Article

References (31)

1. Reynolds JC. Prokinetic agents: a key in the future of gastroenterology. Gastroenterol Clin North Am 1989; 18: 437-57.
2. Osborne RJ, Slevin ML, Hunter RW, Hamer J. Cardiac arrhythmias during cytotoxic chemotherapy: role of domperidone. Hum Toxicol 1985; 4: 617-26.
3. Bruera E, Villamayor R, Roca E, Barugel M, Tronge J, Chacon R. Q-T interval prolongation and ventricular fibrillation with i.v. domperidone. Cancer Treat Rep 1986; 70: 545-6.
4. Roussak JB, Carey P, Parry H. Cardiac arrest after treatment with intravenous domperidone. BMJ (Clin Res Ed) 1984; 289: 1579.
5. Cameron HA, Reyntjens AJ, Lake-Bakaar G. Cardiac arrest after treatment with intravenous domperidone. BMJ (Clin Res Ed) 1985; 290: 160.
6. Joss RA, Goldhirsch A, Brunner KW, Galeazzi RL. Sudden death in cancer patient on high-dose domperidone. Lancet 1982; 1: 1019.
7. Giaccone G, Bertetto O, Calciati A. Two sudden deaths during prophylactic antiemetic treatment with high doses of domperidone and methylprednisolone. Lancet 1984; 2: 1336-7.
8. Djeddi D, Kongolo G, Lefaix C, Mounard J, Léké A. Effect of domperidone on QT interval in neonates. J Pediatr 2008; 153: 663-6.
9. Günlemez A, Babaoǧlu A, Arisoy AE, Türker G, Gökalp AS. Effect of domperidone on the QTc interval in premature infants. J Perinatol 2010; 30: 50-3.
10. Heykants J, Hendriks R, Meuldermans W, Michiels M, Scheygrond H, Reyntjens H. On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokinet 1981; 6: 61-70.
11. Ward BA, Morocho A, Kandil A, Galinsky RE, Flockhart DA, Desta Z. Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol 2004; 58: 277-87.
12. Meuldermans W, Hurkmans R, Swysen E, Hendrickx J, Michiels M, Lauwers W, Heykants J. On the pharmacokinetics of domperidone in animals and man III. Comparative study on the excretion and metabolism of domperidone in rats, dogs and man. Eur J Drug Metab Pharmacokinet 1981; 6: 49-60.
13. Tsujikawa K, Dan Y, Nogawa K, Sato H, Yamada Y, Murakami H, Ohtani H, Sawada Y, Iga T. Potentiation of domperidone-induced catalepsy by a P-glycoprotein inhibitor, cyclosporin A. Biopharm Drug Dispos 2003; 24: 105-14.
14. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97: 2517-24.
15. Zimmermann M, Duruz H, Guinand O, Broccard O, Levy P, Lacatis D, Bloch A. Torsades de Pointes after treatment with terfenadine and ketoconazole. Eur Heart J 1992; 13: 1002-3.
16. Tsai WC, Tsai LM, Chen JH. Combined use of astemizole and ketoconazole resulting in torsade de pointes. J Formos Med Assoc 1997; 96: 144-6.
17. Wysowski DK, Corken A, Gallo-Torres H, Talarico L, Rodriguez EM. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001; 96: 1698-703.
18. Drolet B, Rousseau G, Daleau P, Cardinal R, Turgeon J. Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation 2000; 102: 1883-5.
19. Wilkinson GR. Clearance approaches in pharmacology. Pharmacol Rev 1987; 39: 1-47.
20. Veronese ML, Gillen LP, Burke JP, Dorval EP, Hauck WW, Pequignot E, Waldman SA, Greenberg HE. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J Clin Pharmacol 2003; 43: 831-9.
21. Greenblatt DJ, von Moltke LL, Harmatz JS, Chen G, Weemhoff JL, Jen C, Kelley CJ, LeDuc BW, Zinny MA. Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. Clin Pharmacol Ther 2003; 74: 121-9.
22. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther 2002; 303: 323-32.
23. Benton RE, Sale M, Flockhart DA, Woosley RL. Greater quinidine-induced QTc interval prolongation in women. Clin Pharmacol Ther 2000; 67: 413-8.
24. Rodriguez I, Kilborn MJ, Liu XK, Pezzullo JC, Woosley RL. Drug-induced QT prolongation in women during the menstrual cycle. JAMA 2001; 14: 1322-6.
25. Dumaine R, Roy ML, Brown AM. Blockade of HERG and Kv1.5 by ketoconazole. J Pharmacol Exp Ther 1998; 286: 727-35.
26. Mok NS, Lo YK, Tsui PT, Lam CW. Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug. J Cardiovasc Electrophysiol 2005; 16: 1375-7.
27. 1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. Br J Clin Pharmacol 2005; 59: 346-54.
28. Sarapa N, Nickens DJ, Raber SR, Reynolds RR, Amantea MA. Ritonavir 100mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies. Clin Pharmacol Ther 2008; 83: 153-9.
29. US Food and Drug Administration. International Conference on Harmonisation (ICH) guidance document Topic E14. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. CHMP/ICH/2/04, (2005).
30. Rocha CM, Barbosa MM. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol 2005; 26: 720-3.
31. Medicines Control Council. Interaction between ketoconazole and domperidone and the risk of QT prolongation - important safety information. S Afr Med J 2006; 96: 596.